Abcam founder urges investors to vote against Danaher's $5.7B buyout, seeks to return as CEO
After making clear his opposition to Danaher’s buyout of Abcam, Jonathan Milner — Abcam’s founder and former CEO — is waging a campaign to take back control.
In an open letter, Milner urged Abcam shareholders to vote against the $5.7 billion acquisition, which values Abcam’s protein research tools business at $24 per share. Blasting the leadership team’s “inadequate governance, lacklustre investor relations, deficient cost controls, and subpar execution,” he also reiterated his call for ousting the current CEO, CFO and chairman and spelled out plans to reinstall himself as full-time CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.